OMIDEON

Updated 10 days ago
Private Limited Company
  • Active - SC659801 (CH)
  • Age: 3 years
  • ID: 48796090/18
Doubledykes Road St.Andrews Fife Scotland, KY16 9DR
CLICK HERE TO SEE DETAILS OF COMPANY CHANGES
• 72110 - Research and experimental development on biotechnology
Omideon is focused on developing novel treatments for cancer by targeting the tumour glycome. We have developed carbohydrate binding molecules (CBMs) as a new therapeutic modality for this devastating disease. Omideon's lead candidate OMI-DG1, is a first-in-class multivalent CBM in development for ovarian cancer and colorectal cancer... Omideon's lead candidate, OMI-DG1, is a first-in-class multivalent CBM (mCBM) in development for the treatment of ovarian cancer and colorectal cancer. OMI-DG1 has shown preclinical in vivo proof of concept against ovarian cancer. Omideon has successfully raised investment to expand the indication of OMI-DG1 for colorectal cancer. The Company is currently raising financing to progress OMI-DG1 for both indications into an advanced preclinical oncology product.
Also known as: OMIDEON LIMITED, OMIDEON LTD
Registration numbers: SC659801 (CH)
Primary location: St.andrews United Kingdom
  • 0
  • 0
Interest Score
1
HIT Score
0.64
General
in..@omideon.com

UK Company Data

Company number
SC659801		 Account category
TOTAL EXEMPTION FULL		 Account ref. day
31		 Account ref. month
12
Accounts next due date
2025-09-30		 Accounts last made up date
2023-12-31		 Returns next due date
2021-05-21		 Returns last made up date
N/A
Num. mort. charges
0		 Num. mort. outstanding
0		 Num. mort. part. satisfied
0		 Num. mort. satisfied
0
Num. gen. partners
0		 Num. lim. partners
0
Domain
omideon.com
Actual
www.omideon.com
IP
77.68.2.47
Status
OK
Category
Company
0 comments Add a comment